Navigation Links
Zeus: Dedicated to Advancing Biomaterial Technology with Enhanced Capabilities
Date:9/30/2009

ORANGEBURG, S.C., Sept. 30 /PRNewswire/ -- Zeus Inc., a global leader in material science and the manufacture of fluoropolymer tubing, announces its new state-of-the-art advanced materials laboratory dedicated exclusively to the extrusion, analysis, and characterization of Absorv(TM) Bioabsorbables. Zeus has also expanded its Absorv Bioabsorbables capabilities, including precision tubing ranging from outer diameters of 0.012in to 0.250in and tolerances as tight as +\- 0.0005in.

"Zeus has a history of being at the forefront of cutting-edge technology in polymer science and we are continuing that tradition in the field of absorbable materials," said Dr. Bruce Anneaux, Corporate Manager, Research & Development. "We have devoted an entirely new area to the development of bioabsorbables as these polymers will play a significant role in modern medical device design and next-generation therapies."

Zeus has dedicated 5,000 sq ft of laboratory space for the exploration and production of Absorv Bioabsorbables. The new facility is a controlled environment with an integral Class V clean room. The laboratory is staffed with a team of leading scientists, engineers, and technicians who are highly skilled and experienced in the field of biomaterial development. Laboratory staff also includes regulatory engineers and quality control personnel who are working to pursue new certification levels.

"Not only have we expanded our facilities and technical staff, but we have also designated a portion of our sales force to work solely with our partners in the field of bioabsorbables. Zeus has seen tremendous response to initial efforts within this field and it quickly became apparent we needed specific focus on this emerging product line," said Josh Ridley, Business Development Manager - Biomaterials. "Our goal is to help companies expand or improve their standard offerings through new processing and product forms."

Enhanced properties
'/>"/>

SOURCE Zeus, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases
2. First Seed Sales of Dedicated Energy Crops Begin
3. Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience
4. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
5. American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health
6. International Society for Stem Cell Research Applauds Outcome of Proposal 2 Advancing Stem Cell Research
7. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
8. Nuclear fusion research key to advancing computer chips
9. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
10. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
11. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: ... develops and commercializes proprietary technologies and products for ... has received approval from the TSX Venture Exchange ... share purchase warrants ("the Warrants") of the Company, ... May 2013 private placement financing. Each ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2
... Antidepressant Can Help Adults Living With ... Relief -(1), PRINCETON, N.J. and TOKYO, Nov. ... and Otsuka Pharmaceutical Co.,Ltd. announced today that the ... New Drug Application for ABILIFY(R),(aripiprazole) as adjunctive, or ...
... BB: CLBE), an emerging life sciences company ( http://www.CalbaTech.com ... stem cells for,possible future therapeutic uses and providing products ... to academic,institutions, said today in its 10Q filing with ... be profitable in 2007. The addition of sales ...
... will present at the Piper Jaffray 19th Annual Healthcare ... Pierre Hotel in New York. John L.,Bishop, Chief Executive ... Chief Financial Officer, will provide a corporate overview. ... be,accessed on Cepheid,s Web site at http://www.cepheid.com ...
Cached Biology Technology:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 9CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Wistar Institute have deciphered the structure of the active ... role in the development of nearly all human cancers. ... of new, broadly effective cancer drugs, as well as ... a decade to find drugs that shut down telomerasewidely ...
... have long known to be related to each other women ... Now, a master switch has been found in the brain of ... Biological Studies say it may work the same way in humans. ... Aug. 31 online edition of Nature Medicine , suggest that ...
... was reached by the Alliance for a Healthier Generation ... on "competitive foods" such as soft drinks at schools. ... the availability of soft drinks at school may not ... children. In a study of more than 4,000 ...
Cached Biology News:Landmark study opens door to new cancer, aging treatments 2Landmark study opens door to new cancer, aging treatments 3New master switch found in the brain that regulates appetite and reproduction 2New master switch found in the brain that regulates appetite and reproduction 3New master switch found in the brain that regulates appetite and reproduction 4
... Topo I, Wild Type ... Tris-HCl, 1 mM DTT, 200 µM EDTA, 20% ... topoisomerase I (Topo I) is a monomeric protein ... gene. It catalyzes the relaxation of both positive ...
RNase-Free DNase 50 l...
Request Info...
... is a DNA-dependent RNA polymerase which is ... It efficiently synthesizes in vitro transcripts from ... from a T7 promoter. Transcripts can ... in vitro translation, substrates in RNA processing ...
Biology Products: